Myeloproliferative Neoplasms

In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.

Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Divesiran significantly increased the proportion of clinical responders vs placebo in phlebotomy-dependent polycythemia vera.

Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.

A supplemental new drug application for selinexor plus ruxolitinib for myelofibrosis in August 2026 under the accelerated approval pathway.

Everett Meyer, MD, PhD, discusses the significance of the FDA approval of Orca-T for patients with hematologic malignancies.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Johannes Schetelig, MD, MSc, discusses data for anti–T-lymphocyte globulin vs post-transplant cyclophosphamide for GVHD prophylaxis in hematologic malignancies.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.

Long-term follow-up from the REVIVE and THRIVE studies showed a low thromboembolic event rate with rusfertide in phlebotomy-dependent polycythemia vera.

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Everett Meyer, MD, PhD, discusses the significance of the FDA approval of Orca-T for patients with hematologic malignancies.

Claire Harrison, MD, details the implications of the INDEPENDENCE trial data for luspatercept in myelofibrosis-associated anemia.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Claire Harrison, MD, discusses data for luspatercept in myelofibrosis-associated anemia from the INDEPENDENCE trial.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The FDA approved a prefilled pen for the administration of ropeginterferon alfa-2b-njft in adult patients with polycythemia vera.

Phase 1 data showed that INCA033989 produced rapid and durable responses as monotherapy and in a combination regimen in CALR-mutated myelofibrosis.